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BACKGROUND
Appropriate antithrombotic regimens for patients with atrial fibrillation who have an 
acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) 
are unclear.
METHODS
In an international trial with a two-by-two factorial design, we randomly assigned 
patients with atrial fibrillation who had an acute coronary syndrome or had under-
gone PCI and were planning to take a P2Y
12
 inhibitor to receive apixaban or a vitamin 
K antagonist and to receive aspirin or matching placebo for 6 months. The primary 
outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes 
included death or hospitalization and a composite of ischemic events.
RESULTS
Enrollment included 4614 patients from 33 countries. There were no significant in-
teractions between the two randomization factors on the primary or secondary out-
comes. Major or clinically relevant nonmajor bleeding was noted in 10.5% of the 
patients receiving apixaban, as compared with 14.7% of those receiving a vitamin K 
antagonist (hazard ratio, 0.69; 95% confidence interval [CI], 0.58 to 0.81; P<0.001 
for both noninferiority and superiority), and in 16.1% of the patients receiving aspi-
rin, as compared with 9.0% of those receiving placebo (hazard ratio, 1.89; 95% CI, 
1.59 to 2.24; P<0.001). Patients in the apixaban group had a lower incidence of death 
or hospitalization than those in the vitamin K antagonist group (23.5% vs. 27.4%; 
hazard ratio, 0.83; 95% CI, 0.74 to 0.93; P = 0.002) and a similar incidence of isch-
emic events. Patients in the aspirin group had an incidence of death or hospitaliza-
tion and of ischemic events that was similar to that in the placebo group.
CONCLUSIONS
In patients with atrial fibrillation and a recent acute coronary syndrome or PCI 
treated with a P2Y
12
 inhibitor, an antithrombotic regimen that included apixaban, 
without aspirin, resulted in less bleeding and fewer hospitalizations without signifi-
cant differences in the incidence of ischemic events than regimens that included a 
vitamin K antagonist, aspirin, or both. (Funded by Bristol-Myers Squibb and Pfizer; 
AUGUSTUS ClinicalTrials.gov number, NCT02415400.)
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C
hoosing antithrombotic therapy 
for patients with atrial fibrillation who 
have an acute coronary syndrome or have 
undergone percutaneous coronary intervention 
(PCI) is challenging. Oral anticoagulation is in-
dicated to prevent stroke and systemic embolism 
in patients with atrial fibrillation but has not been 
shown to prevent stent thrombosis and is gener-
ally not indicated for secondary prevention after 
acute coronary syndrome.1-3 Dual antiplatelet ther-
apy is proven to reduce the incidence of recurrent 
ischemic events and stent thrombosis but is less 
effective in reducing the incidence of cardioem-
bolic stroke associated with atrial fibrillation.2-4 
The combination of antithrombotic agents, par-
ticularly triple therapy with oral anticoagulation 
and dual antiplatelet therapy, increases the risk of 
bleeding.5-7 Thus, an oral antithrombotic regimen 
with an acceptable benefit–risk profile would be 
useful in the treatment of patients with atrial fi-
brillation and concomitant acute coronary syn-
drome or PCI. Regimens including non–vitamin K 
antagonist oral anticoagulants appear to offer a 
number of advantages over vitamin K antagonists, 
including the potential for less bleeding.8
Two trials evaluated standard or reduced doses 
of oral anticoagulants (of dabigatran and rivaroxa-
ban, respectively) in patients with atrial fibrillation 
who were undergoing PCI, and both trials showed 
a lower incidence of bleeding with new oral anti-
coagulant regimens without aspirin than with vita-
min K antagonist regimens that included aspi-
rin.9,10 Neither trial was designed to assess whether 
the lower incidence of bleeding was due to the use 
of the standard or reduced doses of the new oral 
anticoagulants or to the removal of aspirin thera-
py. We conducted the AUGUSTUS trial (a two-by-
two factorial, randomized, controlled clinical trial) 
to assess the safety and efficacy of standard-dose 
apixaban as compared with a vitamin K antago-
nist and of low-dose aspirin as compared with 
placebo, on a background of concomitant P2Y
12
 
inhibitor therapy for 6 months in patients with 
atrial fibrillation and recent acute coronary syn-
drome or PCI.
Me thods
Trial Oversight
The trial was designed and led by an academic 
steering committee whose members were respon-
sible for the conduct of the trial. The Duke Clinical 
Research Institute (DCRI, Durham, NC) was the 
academic coordinating center. The trial was spon-
sored by Bristol-Myers Squibb and Pfizer. The trial 
protocol (available with the full text of this article 
at NEJM.org) and all subsequent amendments 
were approved by national regulatory agencies in 
participating countries and by institutional review 
boards or ethics committees at participating sites. 
An independent data and safety monitoring board 
reviewed unblinded patient-level data at regular 
intervals during the trial. Although Bristol-Myers 
Squibb assisted with data management, all the 
statistical analyses were performed independently 
at the DCRI. The initial draft of the manuscript 
was written by the first author and revised on the 
basis of comments from the other authors. All 
the authors vouch for the adherence of the trial to 
the protocol, and the first, second, and last authors 
vouch for the accuracy and completeness of the 
data and analysis. No one who is not an author 
contributed to writing the manuscript. The com-
mittee members and participating investigators 
are listed in the Supplementary Appendix, avail-
able at NEJM.org.
Design
The trial rationale and design have been published 
previously.11 In brief, AUGUSTUS was a prospec-
tive, multicenter, two-by-two factorial, randomized 
clinical trial comparing apixaban with a vitamin K 
antagonist and comparing aspirin with placebo 
in patients with atrial fibrillation who had a re-
cent acute coronary syndrome or underwent PCI 
(or both).
Trial Population
Patients who met all the following criteria were 
eligible for inclusion: an age of at least 18 years; 
previous, persistent, permanent, or paroxysmal 
atrial fibrillation and planned long-term use of 
an oral anticoagulant; recent acute coronary syn-
drome or PCI; and planned use of a P2Y
12
 inhibitor 
for at least 6 months. Patients who were using 
anticoagulation for other conditions (e.g., pros-
thetic valves, venous thromboembolism, and mi-
tral stenosis) were not eligible. Other key exclusion 
criteria were severe renal insufficiency, a history 
of intracranial hemorrhage, recent or planned 
coronary-artery bypass graft surgery, coagulopa-
thy or ongoing bleeding, and contraindication to 
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a vitamin K antagonist, apixaban, all P2Y
12
 inhibi-
tors, or aspirin. All the patients provided written 
informed consent before enrollment.
Stroke and bleeding risks were assessed with 
the use of two scores (Table S1 in the Supplemen-
tary Appendix). CHA
2
DS
2
-VASc scores reflect the 
risk of stroke among patients with atrial fibrilla-
tion who are not receiving anticoagulant therapy; 
scores range from 0 to 9, with higher scores indi-
cating greater risk. HAS-BLED scores reflect the 
risk of bleeding among patients with atrial fibril-
lation who are receiving anticoagulant therapy; 
scores range from 0 to 9, with higher scores indi-
cating greater risk.
Trial Regimen
Patients underwent randomization within 14 days 
after having an acute coronary syndrome or under-
going PCI, with explicit guidance provided to en-
roll eligible patients and start the trial regimen as 
soon as possible after the index event once paren-
teral anticoagulation had been stopped. To be eli-
gible, patients were required to be planning to use 
an approved P2Y
12
 inhibitor for at least 6 months. 
The choice of P2Y
12
 inhibitor was left to the dis-
cretion of the treating physician.
After enrollment into this trial that had a two-
by-two factorial design, patients were randomly 
assigned by means of an interactive voice-response 
system to receive apixaban or a vitamin K antago-
nist and to receive aspirin or matching placebo. 
The treatment regimen comparing apixaban with 
a vitamin K antagonist was open-label; however, 
the regimen comparing aspirin with matching 
placebo was double-blind.
Randomization was stratified according to indi-
cation (acute coronary syndrome or PCI) at enroll-
ment. In accordance with the apixaban label in-
structions for stroke prevention in patients with 
atrial fibrillation, patients who had been randomly 
assigned to receive apixaban were directed to take 
5 mg twice daily or to take 2.5 mg twice daily if 
they met two or more of the following dose-reduc-
tion criteria: were at least 80 years of age, had a 
weight of no more than 60 kg, or had a creatinine 
level of at least 1.5 mg per deciliter (133 µmol per 
liter). Patients who had been randomly assigned to 
receive a vitamin K antagonist had the dose ad-
justed to reach a target international normalized 
ratio (INR) within a range of 2.0 to 3.0. Regarding 
the comparison of aspirin with placebo, patients 
received aspirin at a dose of 81 mg or a matching 
placebo once daily. After 6 months, patients were 
transitioned from their two trial interventions to 
receive antiplatelet and anticoagulant therapy ac-
cording to the local standard of care.
Outcomes
All the patients who underwent randomization 
were to be followed through 6 months, with an 
additional visit at month 7 to record transitions 
in antithrombotic therapy and associated out-
comes. The primary outcome for both factorial 
comparisons was major or clinically relevant non-
major bleeding as defined by the International 
Society on Thrombosis and Haemostasis (ISTH). 
ISTH major bleeding was defined as bleeding that 
resulted in death, occurred in a critical organ (in-
tracranial, intraspinal, intraocular, retroperitoneal, 
intraarticular, intramuscular with compartment 
syndrome, or pericardial), or was associated with 
either a decrease in the hemoglobin level of at 
least 2 g per deciliter or a transfusion of at least 
2 units of packed red cells.12 Clinically relevant 
nonmajor bleeding was defined as bleeding that 
resulted in hospitalization, medical or surgical in-
tervention for bleeding, an unscheduled clinic visit, 
or a change in physician-directed antithrombotic 
therapy. Bleeding was also classified according to 
the Global Use of Strategies to Open Occluded 
Arteries (GUSTO) and Thrombolysis in Myocardial 
Infarction (TIMI) definitions (see the Supplemen-
tary Appendix).13,14
Secondary outcomes included the composite 
of death or hospitalization and the composite of 
death or ischemic events (stroke, myocardial in-
farction, stent thrombosis [definite or probable], or 
urgent revascularization). Exploratory outcomes 
included individual components of the secondary 
outcomes. All bleeding and ischemic events (ex-
cept for urgent revascularization) were indepen-
dently adjudicated by the clinical-events classifi-
cation committee at the DCRI, whose members 
were unaware of the trial-group assignments.
Statistical Analysis
The trial used a factorial design to evaluate two 
independent hypotheses. One hypothesis was that 
apixaban would be at least noninferior, and pos-
sibly superior, to a vitamin K antagonist with re-
gard to the outcome of ISTH major or clinically 
relevant nonmajor bleeding in patients with atrial 
fibrillation and recent acute coronary syndrome 
or PCI and planned concomitant antiplatelet ther-
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF SHEFFIELD on March 20, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 4
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
apy. The second hypothesis was that single anti-
platelet therapy with a P2Y
12
 inhibitor would be 
superior to dual antiplatelet therapy with a P2Y
12
 
inhibitor and aspirin with regard to the outcome 
of ISTH major or clinically relevant nonmajor 
bleeding in patients with atrial fibrillation and re-
cent acute coronary syndrome or PCI and planned 
concomitant anticoagulant therapy.
The population for the primary outcome anal-
ysis included all the patients who underwent ran-
domization and received at least one dose of a 
trial drug or placebo. Events were counted from 
the beginning of receipt of the trial intervention 
through 2 days after the permanent discontinu-
ation of the relevant drug or placebo. The popu-
lation for the two secondary outcome analyses 
included all the patients who underwent ran-
domization according to the randomized groups, 
and all events were counted from randomization 
through the 6-month visit.
Using a log-rank test to compare apixaban 
with a vitamin K antagonist, we estimated that 
357 patients with primary-outcome events among 
4600 patients who had undergone randomiza-
tion would provide the trial with 77% power to 
detect a prespecified noninferiority relative mar-
gin of 1.2 at the upper one-sided 97.5% level of 
confidence, assuming a 1% annual loss to fol-
low-up. Interaction between the two randomiza-
tion factors (oral anticoagulant and aspirin) on the 
primary and secondary outcomes was assessed, 
with stratification according to the index event. 
If there was no significant interaction, the two 
factors were analyzed independently.
If noninferiority of apixaban as compared 
with a vitamin K antagonist was met, we used a 
prespecified hierarchical testing procedure by 
sequentially testing for the superiority of apixa-
ban over a vitamin K antagonist for the following 
outcomes (in order): the composite of ISTH ma-
jor or clinically relevant nonmajor bleeding (pri-
mary safety outcome), the composite of death or 
hospitalization, and the composite of death or 
ischemic events. If superiority was not met in any 
test, P values would not be reported for this or 
subsequent outcomes. P values were calculated 
for interaction tests of prespecified subgroups. 
Hierarchical testing was performed in the same 
way for aspirin as compared with placebo, except 
that the initial noninferiority test on the primary 
outcome was omitted. All P values for superiority 
were two-sided.
The analysis of the time to the first primary 
safety outcome was performed with the use of a 
Cox proportional-hazards model that included an-
ticoagulant-regimen group (apixaban or vitamin K 
antagonist) as a covariate, stratified according to 
the index event (any acute coronary syndrome or 
elective PCI) and the antiplatelet-regimen group 
(aspirin or placebo). A similar comparison was 
performed for the time to the first primary safety 
outcome for the comparison of aspirin with pla-
cebo. Denominators for presented percentages 
represent nonmissing values, unless otherwise 
indicated. All the statistical analyses were per-
formed with the use of SAS software, version 9.4 
(SAS Institute).
R esult s
Patients
From September 2015 through April 2018, a to-
tal of 4614 patients from 492 sites in 33 coun-
tries were randomly assigned to receive open-label 
apixaban or a vitamin K antagonist and to receive 
double-blind aspirin or matching placebo. The 
median time from the index event to randomiza-
tion was 6 days (interquartile range, 3 to 10).
The characteristics of the patients at baseline 
were well balanced among the trial groups (Ta-
ble 1). The median age among all the patients was 
70.7 years, and 29.0% of the patients were wom-
en. The prevalence of hypertension involving the 
use of medication; diabetes; heart failure; and 
previous stroke, transient ischemic attack, or 
thromboembolism was similar in the trial groups. 
Among the patients who underwent randomiza-
tion, 1714 of 4595 (37.3%) had acute coronary 
syndrome and underwent PCI, 1097 (23.9%) had 
medically managed acute coronary syndrome, and 
1784 (38.8%) underwent elective PCI. The me-
dian CHA
2
DS
2
-VASc score was 4 (interquartile 
range, 3 to 5), and the median HAS-BLED score 
was 3 (interquartile range, 2 to 3). Less than one 
third of the patients (29.0%) had previous use of 
a vitamin K antagonist for 30 consecutive days 
at any time, and approximately half the patients 
(49.0%) had recently used an oral anticoagulant 
of any kind, which was discontinued before they 
underwent randomization in the trial.
Clopidogrel was the P2Y
12
 inhibitor used in 
92.6% of the patients. A total of 229 of 2290 pa-
tients (10.0%) who had been randomly assigned 
to receive apixaban received the dose of 2.5 mg 
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Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Apixaban 
(N = 2306)
Vitamin K Antagonist 
(N = 2308)
Aspirin 
(N = 2307)
Aspirin-Matched 
Placebo 
(N = 2307)
Total 
(N = 4614)
Age — yr
Median 70.4 70.9 70.8 70.6 70.7
Interquartile range 64.1–77.2 64.3–77.2 64.4–77.3 63.8–77.2 64.2–77.2
Female sex — no. (%) 670 (29.1) 667 (28.9) 696 (30.2) 641 (27.8) 1337 (29.0)
Race or ethnic group — no./total no. (%)†
White 2097/2282 (91.9) 2087/2275 (91.7) 2082/2276 (91.5) 2102/2281 (92.2) 4184/4557 (91.8)
Black 29/2282 (1.3) 30/2275 (1.3) 29/2276 (1.3) 30/2281 (1.3) 59/4557 (1.3)
Asian 70/2282 (3.1) 70/2275 (3.1) 74/2276 (3.3) 66/2281 (2.9) 140/4557 (3.1)
Native American 10/2282 (0.4) 6/2275 (0.3) 6/2276 (0.3) 10/2281 (0.4) 16/4557 (0.4)
Other 76/2282 (3.3) 82/2275 (3.6) 85/2276 (3.7) 73/2281 (3.2) 158/4557 (3.5)
Serum creatinine — no./total no. (%)‡
<1.5 mg/dl 2101/2274 (92.4) 2051/2258 (90.8) 2078/2260 (91.9) 2074/2272 (91.3) 4152/4532 (91.6)
≥1.5 mg/dl 173/2274 (7.6) 207/2258 (9.2) 182/2260 (8.1) 198/2272 (8.7) 380/4532 (8.4)
CHA2DS2-VASc score§ 3.9±1.6 4.0±1.6 3.9±1.6 3.9±1.6 3.9±1.6
HAS-BLED score¶ 2.9±1.0 2.9±0.9 2.8±0.9 2.9±1.0 2.9±0.9
Hypertension leading to medication use — no. (%) 2042 (88.6) 2031 (88.0) 2031 (88.0) 2042 (88.5) 4073 (88.3)
Heart failure — no. (%) 975 (42.3) 998 (43.2) 982 (42.6) 991 (43.0) 1973 (42.8)
Diabetes mellitus — no. (%) 842 (36.5) 836 (36.2) 842 (36.5) 836 (36.2) 1678 (36.4)
Stroke, TIA, or thromboembolism — no./total no. (%) 326/2289 (14.2) 307/2292 (13.4) 297/2289 (13.0) 336/2292 (14.7) 633/4581 (13.8)
Concomitant P2Y12 inhibitor at randomization — no./total no. (%)
Clopidogrel 2105/2253 (93.4) 2060/2243 (91.8) 2075/2253 (92.1) 2090/2243 (93.2) 4165/4496 (92.6)
Prasugrel 27/2253 (1.2) 24/2243 (1.1) 31/2253 (1.4) 20/2243 (0.9) 51/4496 (1.1)
Ticagrelor 121/2253 (5.4) 159/2243 (7.1) 147/2253 (6.5) 133/2243 (5.9) 280/4496 (6.2)
Previous use of oral anticoagulant — no. (%)‖ 1192 (51.7) 1070 (46.4) 1132 (49.1) 1130 (49.0) 2262 (49.0)
Qualifying index event — no./total no. (%)
Acute coronary syndrome and PCI 873/2297 (38.0) 841/2298 (36.6) 844/2293 (36.8) 870/2302 (37.8) 1714/4595 (37.3)
Medically managed acute coronary syndrome 547/2297 (23.8) 550/2298 (23.9) 547/2293 (23.9) 550/2302 (23.9) 1097/4595 (23.9)
Elective PCI 877/2297 (38.2) 907/2298 (39.5) 902/2293 (39.3) 882/2302 (38.3) 1784/4595 (38.8)
No. of days from acute coronary syndrome or PCI to randomization** 6.7±4.2 6.6±4.2 6.7±4.3 6.5±4.1 6.6±4.2
*  Plus–minus values are means ±SD. The characteristics of the patients at baseline were well balanced among the trial groups. PCI denotes percutaneous coronary intervention, and TIA 
transient ischemic attack.
†  Race or ethnic group was determined by the investigator and recorded on the case-report form.
‡  To convert the values for creatinine to micromoles per liter, multiply by 88.4.
§  CHA2DS2-VASc scores reflect the risk of stroke, with values ranging from 0 to 9 and with higher scores indicating greater risk (Table S1 in the Supplementary Appendix).
¶  HAS-BLED scores reflect the risk of major bleeding, with values ranging from 0 to 9 and with higher scores indicating greater risk (Table S1 in the Supplementary Appendix).
‖  Shown are the numbers of patients who discontinued use of any oral anticoagulant on or before the date of randomization.
**  If the patient both had acute coronary syndrome and underwent PCI within 14 days before randomization, the date of acute coronary syndrome was used.
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twice daily. The median percentage of time in the 
therapeutic range, as calculated by the Rosendaal 
method,15 was 59% among patients assigned to 
receive a vitamin K antagonist (Table S2 in the 
Supplementary Appendix). The median percentage 
of time that patients assigned to a vitamin K an-
tagonist had an INR above 3.0 was 3%, and the 
median percentage of time with an INR below 
2.0 was 23% (Table S2 in the Supplementary Ap-
pendix).
Among the patients receiving oral anticoagu-
lation, 12.7% stopped apixaban and 13.8% stopped 
the vitamin K antagonist before completion of the 
trial. Among the patients receiving aspirin or pla-
cebo, 16.9% stopped aspirin and 14.8% stopped 
placebo before completion of the trial (Fig. 1). A 
total of 13 patients (0.3%) were lost to follow-up 
for vital status, and the proportions were balanced 
among the groups (Fig. 1).
Bleeding
No significant interaction was noted between the 
two randomization factors with regard to the pri-
mary outcome (P = 0.64 for interaction) (Table S3 
in the Supplementary Appendix). At 6 months, 
241 of 2290 patients (10.5%) receiving apixaban 
had an ISTH major or clinically relevant nonma-
jor bleeding event, as compared with 332 of 2259 
(14.7%) receiving a vitamin K antagonist, resulting 
in an event rate per 100 patient-years that was sig-
nificantly lower among patients receiving apixaban 
than among those receiving a vitamin K antago-
nist (hazard ratio, 0.69; 95% confidence interval 
[CI], 0.58 to 0.81), which met the prespecified 
criteria for both noninferiority (P<0.001) and supe-
riority (P<0.001) (Fig. 2A and Table 2). The number 
needed to treat over a period of 6 months to avoid 
one ISTH major or clinically relevant nonmajor 
bleeding event with apixaban instead of a vita-
min K antagonist was 24.
In the antiplatelet-regimen comparison, 367 of 
2277 patients (16.1%) receiving aspirin had an 
ISTH major or clinically relevant nonmajor bleed-
ing event, as compared with 204 of 2279 (9.0%) 
receiving placebo. The event rate was significantly 
higher among those receiving aspirin than among 
those receiving placebo (hazard ratio, 1.89; 95% CI, 
1.59 to 2.24; P<0.001) (Fig. 2B and Table 2). The 
number needed to harm over a period of 6 months 
to cause one ISTH major or clinically relevant non-
major bleeding event with aspirin instead of pla-
cebo was 14.
The percentage of patients with a primary 
bleeding outcome event was highest among those 
receiving a vitamin K antagonist and aspirin 
(18.7%) and lowest among those receiving apix-
aban and placebo (7.3%) (Fig. 2C, and Table S4A 
in the Supplementary Appendix). Similar effects 
were observed with regard to major bleeding and 
to bleeding assessed with the use of other bleed-
ing scales (Table 3). The effects of apixaban as 
compared with a vitamin K antagonist and of 
aspirin as compared with placebo were generally 
consistent across prespecified subgroups with re-
gard to bleeding events (Fig. S1A and S1B in the 
Supplementary Appendix).
Death or Hospitalization
No significant interaction was observed between 
the two randomization factors with regard to 
death or hospitalization (P = 0.21 for interaction) 
(Table S3 in the Supplementary Appendix). At 
6 months, 541 patients (23.5%) who had been as-
signed to receive apixaban had died or had been 
hospitalized, as compared with 632 (27.4%) who 
had been assigned to receive a vitamin K antago-
nist (Table 2). The event rate per 100 patient-years 
for death or hospitalization at 6 months was lower 
among patients assigned to receive apixaban than 
among those assigned to receive a vitamin K an-
tagonist (hazard ratio, 0.83; 95% CI, 0.74 to 0.93; 
P = 0.002) (Fig. 3A). The difference between groups 
was driven by a lower incidence of hospitalization 
(518 patients [22.5%] in the apixaban group vs. 
607 [26.3%] in the vitamin K antagonist group) 
since the frequencies of death were similar. The 
number needed to treat over a period of 6 months 
to avoid one death or hospitalization with apixa-
ban instead of a vitamin K antagonist was 26.
In the antiplatelet-regimen comparison, 604 
patients (26.2%) who had been assigned to receive 
aspirin died or were hospitalized, as compared 
with 569 (24.7%) who had been assigned to receive 
placebo (Table 2). Patients who had been assigned 
to receive aspirin had an incidence of death or 
hospitalization at 6 months that was similar to 
that among patients assigned to receive placebo 
(hazard ratio, 1.08; 95% CI, 0.96 to 1.21) (Fig. 3B). 
The cumulative incidence of death or hospitaliza-
tion at 6 months was highest among patients 
who had been assigned to receive a vitamin K 
antagonist and aspirin (27.5%) and lowest among 
those assigned to receive apixaban and placebo 
(22.0%) (Fig. 3C, and Table S4B in the Supplemen-
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tary Appendix). The effects of apixaban as com-
pared with a vitamin K antagonist and of aspirin 
as compared with placebo were generally consis-
tent across prespecified subgroups with regard to 
death or hospitalization (Fig. S2A and S2B in the 
Supplementary Appendix).
Ischemic Events
No significant interaction was found between the 
two randomization factors with regard to death 
or ischemic events (P = 0.28 for interaction) (Table 
S3 in the Supplementary Appendix). At 6 months, 
154 patients (6.7%) who had been assigned to 
receive apixaban had died or had had an ischemic 
event — including myocardial infarction, definite 
or probable stent thrombosis, stroke, or urgent 
revascularization — as compared with 163 (7.1%) 
who had been assigned to receive a vitamin K 
antagonist (Table 2). In the antiplatelet-regimen 
comparison, 149 patients (6.5%) who had been as-
signed to receive aspirin died or had an ischemic 
event, as compared with 168 (7.3%) who had been 
Figure 1. Enrollment, Randomization, and Follow-up.
Patients underwent randomization in this trial, which had a two-by-two factorial design, to receive either apixaban or a vitamin K  
antagonist and also to receive either aspirin or matching placebo.
4614 Underwent randomization
4683 Patients were assessed
for eligibility
69 Were not eligible
19 Did not meet inclusion
criteria
39 Met exclusion criteria
11 Had unknown reason
2306 Were assigned to receive
apixaban
547 Had medically managed
acute coronary syndrome
873 Had acute coronary
syndrome and underwent
percutaneous coronary
intervention
877 Underwent elective 
percutaneous coronary
intervention
9 Had no data reported
2308 Were assigned to receive
vitamin K antagonist
550 Had medically managed
acute coronary syndrome
841 Had acute coronary
syndrome and underwent
percutaneous coronary
intervention
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percutaneous coronary
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10 Had no data reported
2290 Received at least one dose
of apixaban
1999 Completed intervention
291 Did not complete 
intervention
2259 Received at least one dose
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1948 Completed intervention
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intervention
2161 Completed trial
129 Did not complete trial
88 Died
6 Were lost to follow-up
29 Withdrew consent
6 Had other reason
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149 Did not complete trial
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7 Were lost to follow-up
46 Withdrew consent
14 Had other reason
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aspirin
547 Had medically managed
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550 Had medically managed
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5 Had no data reported
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of aspirin
1892 Completed intervention
385 Did not complete 
intervention
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of placebo
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intervention
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140 Did not complete trial
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5 Were lost to follow-up
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assigned to receive placebo (Table 2). This differ-
ence was not significant, but more ischemic events 
occurred in the placebo group.
The overall event rates per 100 patient-years for 
death or ischemic events were similar in the anti-
coagulant-regimen and antiplatelet-regimen com-
parisons (Table 3). The event rate per 100 patient-
years for stroke was lower among patients receiving 
apixaban than among those receiving a vitamin K 
antagonist (hazard ratio, 0.50; 95% CI, 0.26 to 
0.97) (Table 3). The effects of apixaban as com-
pared with a vitamin K antagonist and of aspirin 
as compared with placebo were generally consis-
tent across prespecified subgroups with regard to 
death or ischemic events (Fig. S3A and S3B in the 
Supplementary Appendix).
Outcome Apixaban Vitamin K Antagonist
Hazard Ratio 
(95% CI)
P Value for 
Superiority
Anticoagulation-regimen comparison
I  m  c	c
 rr	 		m
bleeding†
No. of patients with event/total no. (%) 241/2290 (10.5) 332/2259 (14.7) — —
Event rate per 100 patient-yr 24.7 35.8 0.69 (0.58–0.81) <0.001
Death or hospitalization
No. of patients with event/total no. (%) 541/2306 (23.5) 632/2308 (27.4) — —
Event rate per 100 patient-yr 57.2 69.2 0.83 (0.74–0.93) 0.002
Death or ischemic event‡
No. of patients with event/total no. (%) 154/2306 (6.7) 163/2308 (7.1) — —
Event rate per 100 patient-yr 14.3 15.3 0.93 (0.75–1.16) NS
Antiplatelet-regimen comparison Aspirin Placebo
ISTH major or clinically relevant nonmajor 
bleeding
No. of patients with event/total no. (%) 367/2277 (16.1) 204/2279 (9.0) — —
Event rate per 100 patient-yr 40.5 21.0 1.89 (1.59–2.24) <0.001
Death or hospitalization§
No. of patients with event/total no. (%) 604/2307 (26.2) 569/2307 (24.7) — —
Event rate per 100 patient-yr 65.7 60.6 1.08 (0.96–1.21) NS
Death or ischemic event
No. of patients with event/total no. (%) 149/2307 (6.5) 168/2307 (7.3) — —
Event rate per 100 patient-yr 13.9 15.7 0.89 (0.71–1.11) NT
*  The hazard ratios were calculated by the Cox proportional-hazards model for time to the first event, stratified according to indication at en-
rollment and either the antiplatelet regimen (in the analysis of the anticoagulant-regimen comparison) or the anticoagulant regimen (in the 
analysis of the antiplatelet-regimen comparison). All P values for superiority are two-sided. ISTH denotes International Society on 
Thrombosis and Haemostasis, NS not significant, and NT not tested.
†  The result of the noninferiority test comparing the time to the first primary safety event in the apixaban group with that in the vitamin K an-
tagonist group was significant (P<0.001).
‡  This analysis had the first nonsignificant result in the hierarchical testing procedure for the outcomes assessed in the anticoagulant-regimen 
comparison.
§  This analysis had the first nonsignificant result in the hierarchical testing procedure for the outcomes assessed in the antiplatelet-regimen 
comparison.
Table 2. Primary Safety and Secondary Efficacy Outcomes.*
Figure 2 (facing page). Kaplan–Meier Curves for  
Primary Outcome of Major or Clinically Relevant  
Nonmajor Bleeding.
The primary outcome was major or clinically relevant 
nonmajor bleeding as defined by the International  
Society on Thrombosis and Haemostasis. Insets show 
the same data on an enlarged y axis.
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Table 3. Additional Safety and Efficacy Outcomes of Interest.*
Outcome Anticoagulant-Regimen Comparison Antiplatelet-Regimen Comparison
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Efficacy outcomes
3 4 5 4 7 8 9 : ; < = : > ; = 9 = 9 ? @ > ; > 2306 2308 2307 2307
B 4 > 8 ; : 9 ? ; D 9 : ; 4 =
No. of patients with event (%) 518 (22.5) 607 (26.3) — 585 (25.4) 540 (23.4) —
Event rate per 100 patient-yr 54.8 66.5 0.83 (0.74–0.93) 63.7 57.5 1.10 (0.98–1.24)
Death
No. of patients with event (%) 77 (3.3) 74 (3.2) — 72 (3.1) 79 (3.4) —
Event rate per 100 patient-yr 7.0 6.7 1.03 (0.75–1.42) 6.6 7.2 0.91 (0.66–1.26)
Death from cardiovascular causes
No. of patients with event (%) 57 (2.5) 54 (2.3) — 53 (2.3) 58 (2.5) —
Event rate per 100 patient-yr 5.2 4.9 1.05 (0.72–1.52) 4.8 5.3 0.92 (0.63–1.33)
Stroke
No. of patients with event (%) 13 (0.6) 26 (1.1) — 20 (0.9) 19 (0.8) —
Event rate per 100 patient-yr 1.2 2.4 0.50 (0.26–0.97) 1.8 1.7 1.06 (0.56–1.98)
Myocardial infarction
No. of patients with event (%) 72 (3.1) 80 (3.5) — 68 (2.9) 84 (3.6) —
Event rate per 100 patient-yr 6.6 7.4 0.89 (0.65–1.23) 6.3 7.8 0.81 (0.59–1.12)
ARC definite or probable stent thrombosis
No. of patients with event (%) 14 (0.6) 18 (0.8) — 11(0.5) 21 (0.9) —
Event rate per 100 patient-yr 1.3 1.6 0.77 (0.38–1.56) 1.0 1.9 0.52 (0.25–1.08)
Urgent revascularization
No. of patients with event (%) 40 (1.7) 44 (1.9) — 37 (1.6) 47 (2.0) —
Event rate per 100 patient-yr 3.7 4.1 0.90 (0.59–1.38) 3.4 4.3 0.79 (0.51–1.21)
*  Safety outcome analyses assessed the patients on an as-treated basis, and efficacy outcome analyses assessed patients according to their randomized group assignment. The hazard ra-
tio was calculated by the Cox proportional-hazards model for time to the first event, stratified according to the indication at enrollment and either the antiplatelet regimen (in the analy-
sis of the anticoagulant-regimen comparison) or the anticoagulant regimen (in the analysis of the antiplatelet-regimen comparison). ARC denotes Academic Research Consortium, 
GUSTO Global Use of Strategies to Open Occluded Arteries, and TIMI Thrombolysis in Myocardial Infarction.
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FiguFe 3. Kaplan–Meier Curves for the Composite of Death or Hospitalization.
C
u
m
u
la
ti
ve
 I
n
ci
d
en
ce
 o
f 
E
ve
n
t 
(%
) 100
80
90
70
60
40
30
10
50
20
0
0 30 60 90 120 150 180
JLMO OQSUW XLSYZ[Q\L]QZS
^ JWL]_ Z` bZOdQ]LfQ\L]QZS h jOdQ`QS kOl nfLUWqZ
A JWL]_ Z` bZOdQ]LfQ\L]QZS h jdQsLqLS kOl tQ]L[QS v jS]LxZSQO]
Hazard ratio for apixaban vs. vitamin K 
antagonist, 0.83 (95% CI, 0.74–0.93)
P=0.002 
Event rate per 100 patient-yr:
Vitamin K antagonist, 69.2
Apixaban, 57.2
Zl L] XQOy
Vitamin K antagonist
Apixaban
2308
2306
2035
2090
1885
1965
1805
1881
1732
1821
1673
1772
1001
947
C
u
m
u
la
ti
ve
 I
n
ci
d
en
ce
 o
f 
E
ve
n
t 
(%
) 100
80
90
70
60
40
30
10
50
20
0
0 30 60 90 120 150 180
JLMO OQSUW XLSYZ[Q\L]QZS
Hazard ratio for aspirin vs. placebo,
1.08 (95% CI, 0.96–1.21)
Event rate per 100 patient-yr:
Aspirin, 65.7
Placebo, 60.6
No. at Risk
Aspirin
Placebo
2307
2307
2042
2083
1909
1941
1822
1864
1752
1801
1699
1746
951
997
C
u
m
u
la
ti
ve
 I
n
ci
d
en
ce
 o
f 
E
ve
n
t 
(%
) 100
80
90
70
60
40
30
10
50
20
0
0 30 60 90 120 150 180
Days since Randomization
Event rate per 100 patient-yr:
Vitamin K antagonist
and aspirin, 69.5
Apixaban and aspirin, 62.0
Vitamin K antagonist
and placebo, 68.9
Apixaban and placebo, 52.7
No. at Risk
Vitamin K antagonist
and aspirin
Apixaban and aspirin
Vitamin K antagonist
and placebo
Apixaban and placebo
1154
1153
1154
1153
1016
1026
1019
1064
939
970
946
995
899
923
906
958
864
888
868
933
836
863
837
909
492
459
509
488
C Death or Hospitalization, According to Intervention Combination
Apixaban
Vitamin K antagonist
Placebo
Aspirin
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF SHEFFIELD on March 20, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 13
Antithrombotic Ther apy in Atrial Fibrillation
Discussion
The current trial was specifically designed to as-
sess the independent effect of anticoagulant and 
antiplatelet therapy in patients with atrial fibril-
lation and recent acute coronary syndrome or PCI 
who were planning to receive a P2Y
12
 inhibitor. 
Apixaban led to a lower incidence of both bleed-
ing and the composite of death or hospitalization 
than did a vitamin K antagonist; the latter result 
was driven by a lower incidence of hospitalization. 
The overall incidence of ischemic events was simi-
lar in the two groups. Aspirin led to a higher in-
cidence of bleeding than placebo, and the rates of 
death or hospitalization and of ischemic events 
were similar in the two groups. A regimen of 
clopidogrel plus apixaban, at the dose labeled for 
stroke prevention, without aspirin was not associ-
ated with excess adverse events and appeared to 
be effective in this high-risk group of patients.
Vitamin K antagonists have not been shown to 
prevent stent thrombosis,16-18 and dual antiplate-
let therapy does not provide adequate protection 
against strokes related to atrial fibrillation.19-21 
Observational studies have shown that combined 
dual antiplatelet therapy and a vitamin K antago-
nist (i.e., triple therapy) is associated with a high 
risk of bleeding.5-7 Although there are reasons for 
considering the discontinuation of aspirin ther-
apy,22 the WOEST (What Is the Optimal Antiplate-
let and Anticoagulant Therapy in Patients with 
Oral Anticoagulation and Coronary Stenting) tri-
al23 showed a reduction in both bleeding and ische-
mic events by discontinuing aspirin in patients 
receiving oral anticoagulation with a vitamin K 
antagonist and undergoing PCI, although the trial 
was small and underpowered for such an analysis.
Our results confirm and extend these results 
in a high-risk population of patients with atrial 
fibrillation by showing a lower incidence of major 
or clinically relevant nonmajor bleeding among 
patients treated without aspirin than among those 
treated with aspirin, but we found that the inci-
dence of ischemic events was not significantly 
lower among patients who did not receive aspirin. 
Although the choice of P2Y
12
 inhibitor was left to 
the treating physician, more than 90% of the pa-
tients were treated with clopidogrel instead of the 
more potent agents, which is consistent with most 
guidance statements. We observed a greater num-
ber of coronary ischemic events among patients 
who did not take aspirin than among those who 
did, although event rates were low and the trial 
was not adequately powered to assess differences 
in individual ischemic outcomes. Although this 
analysis should be considered exploratory, similar 
trials have shown a similar pattern of numerically 
more coronary ischemic events when aspirin was 
omitted.9,10 Thus, when clinicians consider aspirin 
as a component of antithrombotic therapy after 
PCI in patients with atrial fibrillation, a potential 
small absolute decrease in the risk of coronary 
ischemic events needs to be weighed against a 
larger absolute increase in the risk of clinically 
significant bleeding.
Although the new oral anticoagulants have 
been shown to be at least as effective as vitamin K 
antagonists for reducing the incidence of thrombo-
embolic events and at least as safe as vitamin K 
antagonists for major bleeding in patients with 
atrial fibrillation, patients receiving dual antiplate-
let therapy were excluded from the pivotal trials 
of these oral agents.8,24-27 The PIONEER AF-PCI 
trial10 compared two antithrombotic regimens, 
involving doses of rivaroxaban lower than the dose 
recommended to prevent stroke risk among pa-
tients with atrial fibrillation (rivaroxaban at a dose 
of 15 mg daily plus a P2Y
12
 inhibitor or rivaroxa-
ban at a dose of 2.5 mg twice daily plus aspirin 
and a P2Y
12
 inhibitor, with a switch to rivaroxaban 
at a dose of 15 mg daily plus aspirin when the 
P2Y
12
 inhibitor was stopped), with a vitamin K 
antagonist plus dual antiplatelet therapy. The inci-
dence of bleeding was significantly lower with 
the two rivaroxaban regimens than with a vita-
min K antagonist, and there was no significant 
increase in the risk of ischemic events, stroke, or 
stent thrombosis.10 The RE-DUAL PCI trial9 com-
pared two antithrombotic regimens, using ap-
proved doses of dabigatran (150 mg twice daily 
or 110 mg twice daily) plus a P2Y
12
 inhibitor, with 
warfarin plus dual antiplatelet therapy. Again, rates 
of bleeding were significantly lower with each of 
the dabigatran-based regimens than with warfa-
rin plus dual antiplatelet therapy, and the risk of 
ischemic events was not significantly higher.9 Both 
these trials compared either lower-than-approved 
doses of a new oral anticoagulant with a full-dose 
vitamin K antagonist (target INR, 2.0 to 3.0) or 
strategies of double therapy (new oral agent plus 
P2Y
12
 inhibitor) with traditional triple therapy (oral 
anticoagulant plus P2Y
12
 inhibitor plus aspirin). 
Given their designs, it is impossible to determine 
whether the lower risk of bleeding that was seen 
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in the new-oral-agent groups was due to the use 
of the new agent, the reduced dose of the agent, 
or the discontinuation of aspirin.
Our trial, AUGUSTUS, confirms the safety and 
efficacy of apixaban, as compared with a vita-
min K antagonist, at a dose recommended for 
patients with atrial fibrillation and shows that 
the effect of avoiding aspirin on the incidence of 
bleeding events seems to be even greater than 
the benefit of using apixaban instead of a vita-
min K antagonist. Our results concur with the 
current North American guidance28 of recom-
mending a new oral anticoagulant plus a P2Y
12
 
inhibitor in this population of patients, but they 
contrast with recent European guidance,29 which 
still recommends triple antithrombotic therapy 
in these patients. Thus, our results support the 
use a regimen of apixaban with a P2Y
12
 inhibitor, 
most commonly clopidogrel, without aspirin in 
a broad population of patients with atrial fibril-
lation and recent acute coronary syndrome or PCI.
Among patients undergoing PCI, 5 to 8% have 
atrial fibrillation, complicating the choice of post-
PCI antithrombotic therapy.30,31 Our trial includ-
ed patients with acute coronary syndrome, which 
was managed medically or with PCI, and patients 
who underwent elective PCI, all of whom are at 
high risk for both bleeding and ischemic events. 
The mean time from the index event to random-
ization was 6.6 days; treatment decisions during 
this time were left to the discretion of the treating 
physician, and many patients probably received as-
pirin during this time. The median CHA
2
DS
2
-VASc 
score was 4, and the median HAS-BLED score 
was 3. This trial shows that, after initial stabiliza-
tion of the index event, the lower rates of bleeding 
with apixaban than with a vitamin K antagonist 
and of placebo than with aspirin on a background 
of a P2Y
12
 inhibitor were preserved, regardless of 
management strategy.
None of the three contemporary trials of the 
new oral anticoagulants in patients with atrial 
fibrillation and PCI, including AUGUSTUS, were 
designed to be large enough to detect small but 
potentially meaningful differences in the inci-
dence of ischemic events. In the PIONEER AF-PCI 
trial, the ischemic event rates were similar among 
the groups, but the rivaroxaban doses that were 
tested were lower than the approved dose for 
stroke prevention in patients with atrial fibrilla-
tion, arousing concerns about the efficacy of these 
regimens with respect to ischemic stroke.10 Al-
though the RE-DUAL PCI trial tested doses of 
dabigatran that had been previously studied in 
the RE-LY (Randomized Evaluation of Long-Term 
Anticoagulant Therapy) trial24 involving patients 
with atrial fibrillation, the rates of myocardial 
infarction and stent thrombosis were nonsignifi-
cantly higher among patients who had been ran-
domly assigned to receive dabigatran at a dose of 
110 mg twice daily without aspirin than among 
those who were assigned to receive warfarin plus 
a P2Y
12
 inhibitor plus aspirin.9
Our trial used doses of apixaban with proven 
efficacy for stroke prevention in patients with 
atrial fibrillation and showed a significantly lower 
rate of death or hospitalization, driven by the in-
cidence of hospitalization, and a 50% lower inci-
dence of stroke than were observed with a vita-
min K antagonist. Our trial provides reassurance 
that, for patients with atrial fibrillation and acute 
coronary syndrome or PCI who are receiving an-
ticoagulation, the use of apixaban at a dose of 
5 mg twice daily is a safe and effective regimen 
that is superior to a vitamin K antagonist. Finally, 
avoiding aspirin resulted in a 47% lower risk of 
bleeding than using aspirin and in a nonsignifi-
cantly higher incidence of coronary ischemic 
events. This finding suggests that the price for a 
significantly lower incidence of bleeding events 
without aspirin may be a modestly higher risk of 
coronary ischemic events.
There are limitations to our trial. The time in 
the therapeutic range for the patients who received 
a vitamin K antagonist was modestly lower than in 
some previous randomized trials of stroke preven-
tion involving patients with atrial fibrillation.19,24-26 
This finding shows real-life challenges with vi-
tamin K antagonist treatment, especially in an in-
ternational setting over a relatively short (6 month) 
period of time. Our trial was not designed to be 
large enough to detect potentially clinically im-
portant differences in less common but impor-
tant individual ischemic outcomes.
In conclusion, in patients with atrial fibrilla-
tion and a recent acute coronary syndrome or 
PCI treated with a P2Y
12
 inhibitor, an antithrom-
botic regimen that included apixaban, without 
aspirin, resulted in less bleeding and fewer hos-
pitalizations without significant differences in 
ischemic events than regimens that included a 
vitamin K antagonist, aspirin, or both.
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